US6254854B1
(en)
|
1996-05-24 |
2001-07-03 |
The Penn Research Foundation |
Porous particles for deep lung delivery
|
US6503480B1
(en)
|
1997-05-23 |
2003-01-07 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
US6433040B1
(en)
|
1997-09-29 |
2002-08-13 |
Inhale Therapeutic Systems, Inc. |
Stabilized bioactive preparations and methods of use
|
US20060165606A1
(en)
|
1997-09-29 |
2006-07-27 |
Nektar Therapeutics |
Pulmonary delivery particles comprising water insoluble or crystalline active agents
|
AU757153B2
(en)
*
|
1997-09-29 |
2003-02-06 |
Novartis Ag |
Stabilized preparations for use in metered dose inhalers
|
US6946117B1
(en)
*
|
1997-09-29 |
2005-09-20 |
Nektar Therapeutics |
Stabilized preparations for use in nebulizers
|
GB9727102D0
(en)
*
|
1997-12-22 |
1998-02-25 |
Andaris Ltd |
Microparticles and their therapeutic use
|
WO2000000215A1
(en)
*
|
1998-06-29 |
2000-01-06 |
Inhale Therapeutic Systems, Inc. |
Particulate delivery systems and methods of use
|
EP1091755A1
(de)
*
|
1998-06-29 |
2001-04-18 |
Alliance Pharmaceutical Corporation |
Teilchenförmige verabreichungsformen und deren verwendung
|
US6630169B1
(en)
|
1999-03-31 |
2003-10-07 |
Nektar Therapeutics |
Particulate delivery systems and methods of use
|
US6223455B1
(en)
†
|
1999-05-03 |
2001-05-01 |
Acusphere, Inc. |
Spray drying apparatus and methods of use
|
NZ516083A
(en)
*
|
1999-05-27 |
2003-08-29 |
Acusphere Inc |
Porous drug matrices and methods of manufacture thereof
|
US6630121B1
(en)
|
1999-06-09 |
2003-10-07 |
The Regents Of The University Of Colorado |
Supercritical fluid-assisted nebulization and bubble drying
|
US6858199B1
(en)
|
2000-06-09 |
2005-02-22 |
Advanced Inhalation Research, Inc. |
High efficient delivery of a large therapeutic mass aerosol
|
CA2382821A1
(en)
*
|
1999-08-25 |
2001-03-01 |
Advanced Inhalation Research, Inc. |
Modulation of release from dry powder formulations
|
US6586008B1
(en)
|
1999-08-25 |
2003-07-01 |
Advanced Inhalation Research, Inc. |
Use of simple amino acids to form porous particles during spray drying
|
WO2001045731A1
(en)
|
1999-12-21 |
2001-06-28 |
Rxkinetix, Inc. |
Particulate drug-containing products and method of manufacture
|
US6761909B1
(en)
|
1999-12-21 |
2004-07-13 |
Rxkinetix, Inc. |
Particulate insulin-containing products and method of manufacture
|
DE60112902T2
(de)
|
2000-02-08 |
2006-06-14 |
3M Innovative Properties Co |
Verfahren und kit zum bereitstellen eines beständigen bilds auf einem substrat
|
US20010031342A1
(en)
|
2000-02-08 |
2001-10-18 |
Engle Lori P. |
Media for cold image transfer
|
GB0003935D0
(en)
*
|
2000-02-08 |
2000-04-12 |
King S College London |
Formulation for dry powder inhaler
|
US7871598B1
(en)
*
|
2000-05-10 |
2011-01-18 |
Novartis Ag |
Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
|
WO2001085136A2
(en)
*
|
2000-05-10 |
2001-11-15 |
Alliance Pharmaceutical Corporation |
Phospholipid-based powders for drug delivery
|
US8404217B2
(en)
*
|
2000-05-10 |
2013-03-26 |
Novartis Ag |
Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
|
WO2001087277A2
(en)
*
|
2000-05-15 |
2001-11-22 |
Vectura Limited |
Method of manufacturing particles
|
NZ523693A
(en)
*
|
2000-07-10 |
2004-08-27 |
Chiron Corp |
Macrolide formulations for inhalation and methods of treatment of endobronchial infections
|
US7141236B2
(en)
|
2000-07-28 |
2006-11-28 |
Nektar Therapeutics |
Methods and compositions for delivering macromolecules to or via the respiratory tract
|
DE10064219B9
(de)
*
|
2000-12-22 |
2009-02-12 |
Nasalis Pain Relief International Gmbh |
Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
|
US20030072717A1
(en)
|
2001-02-23 |
2003-04-17 |
Vapotronics, Inc. |
Inhalation device having an optimized air flow path
|
GB0106403D0
(en)
*
|
2001-03-15 |
2001-05-02 |
Pharmaceutical Profiles |
Labelling of dry powder formulations for inhalation
|
GB0107106D0
(en)
*
|
2001-03-21 |
2001-05-09 |
Boehringer Ingelheim Pharma |
Powder inhaler formulations
|
JP2004528339A
(ja)
*
|
2001-04-26 |
2004-09-16 |
ネクター セラピューティクス |
気道に対して又は気道を介して高分子を送達するための新規方法及び組成物
|
US7905230B2
(en)
|
2001-05-09 |
2011-03-15 |
Novartis Ag |
Metered dose inhaler with lockout
|
EP1389137B1
(de)
*
|
2001-05-21 |
2006-07-19 |
InJet Digital Aerosols Limited |
Zusammensetzungen für die freisetzung von protein auf dem pulmonalen weg
|
US6737042B2
(en)
|
2001-05-24 |
2004-05-18 |
Alexza Molecular Delivery Corporation |
Delivery of drug esters through an inhalation route
|
US6737043B2
(en)
|
2001-05-24 |
2004-05-18 |
Alexza Molecula Delivery Corporation |
Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
|
US6759029B2
(en)
|
2001-05-24 |
2004-07-06 |
Alexza Molecular Delivery Corporation |
Delivery of rizatriptan and zolmitriptan through an inhalation route
|
US7078016B2
(en)
|
2001-11-21 |
2006-07-18 |
Alexza Pharmaceuticals, Inc. |
Delivery of caffeine through an inhalation route
|
US6805853B2
(en)
|
2001-11-09 |
2004-10-19 |
Alexza Molecular Delivery Corporation |
Delivery of diazepam through an inhalation route
|
US20070122353A1
(en)
|
2001-05-24 |
2007-05-31 |
Hale Ron L |
Drug condensation aerosols and kits
|
US7766013B2
(en)
|
2001-06-05 |
2010-08-03 |
Alexza Pharmaceuticals, Inc. |
Aerosol generating method and device
|
US7540284B2
(en)
|
2001-06-20 |
2009-06-02 |
Novartis Pharma Ag |
Powder aerosolization apparatus and method
|
US8337816B2
(en)
*
|
2001-09-17 |
2012-12-25 |
Glaxo Group Limited |
Dry powder medicament formulations
|
EP1446104B2
(de)
|
2001-11-01 |
2011-08-03 |
Novartis AG |
Sprühtrocknungsverfahren
|
JP2005514393A
(ja)
|
2001-12-19 |
2005-05-19 |
ネクター セラピューティクス |
アミノグリコシドの肺への供給
|
JP4739672B2
(ja)
|
2001-12-21 |
2011-08-03 |
ネクター セラピューティクス |
湿気のバリアを有するカプセルパッケージ
|
JPWO2003077891A1
(ja)
*
|
2002-03-18 |
2005-07-14 |
アステラス製薬株式会社 |
吸入用粉末医薬組成物およびその製造方法
|
US7008644B2
(en)
|
2002-03-20 |
2006-03-07 |
Advanced Inhalation Research, Inc. |
Method and apparatus for producing dry particles
|
US9339459B2
(en)
|
2003-04-24 |
2016-05-17 |
Nektar Therapeutics |
Particulate materials
|
US6941980B2
(en)
|
2002-06-27 |
2005-09-13 |
Nektar Therapeutics |
Apparatus and method for filling a receptacle with powder
|
PE20040134A1
(es)
|
2002-07-25 |
2004-03-06 |
Pharmacia Corp |
Forma de dosificacion de una vez al dia de pramipexol
|
AU2003279070A1
(en)
*
|
2002-09-30 |
2004-04-23 |
Acusphere Inc |
Sustained release porous microparticles for inhalation
|
US7516741B2
(en)
|
2002-12-06 |
2009-04-14 |
Novartis Ag |
Aerosolization apparatus with feedback mechanism
|
WO2004054556A1
(en)
*
|
2002-12-13 |
2004-07-01 |
Adagit |
Pharmaceutical porous particles
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
PL378270A1
(pl)
*
|
2002-12-31 |
2006-03-20 |
Nektar Therapeutics |
Preparat farmaceutyczny zawierający nierozpuszczalny środek czynny
|
US7669596B2
(en)
|
2002-12-31 |
2010-03-02 |
Novartis Pharma Ag |
Aerosolization apparatus with rotating capsule
|
WO2004073729A1
(ja)
|
2003-02-21 |
2004-09-02 |
Translational Research Ltd. |
薬物の経鼻投与用組成物
|
CN100353997C
(zh)
|
2003-02-28 |
2007-12-12 |
中外制药株式会社 |
稳定的含蛋白质的制剂
|
WO2004087243A1
(ja)
|
2003-03-27 |
2004-10-14 |
Bioactis Limited |
鼻腔用粉末薬剤施薬装置
|
US8869794B1
(en)
|
2003-04-09 |
2014-10-28 |
Novartis Pharma Ag |
Aerosolization apparatus with capsule puncturing member
|
PT1610850E
(pt)
|
2003-04-09 |
2012-06-15 |
Novartis Ag |
Dispositivo para gerar um aerossol com protecção da entrada de ar
|
SI1615689T1
(sl)
|
2003-04-09 |
2016-05-31 |
Novartis Ag |
Naprava za aerosolizacijo s poravnalnim vodilom za prebadanje kapsule
|
ATE520935T1
(de)
|
2003-05-21 |
2011-09-15 |
Alexza Pharmaceuticals Inc |
Verwendung einer schicht aus festem brennstoff, verfahren zum erstellen einer solchen schicht und zugehörige heizvorrichtung
|
US7862834B2
(en)
|
2003-05-28 |
2011-01-04 |
Novartis Pharma Ag |
Pharmaceutical formulation comprising a water-insoluble active agent
|
EP1667659A1
(de)
*
|
2003-09-30 |
2006-06-14 |
Acusphere, Inc. |
Injizierbare, orale oder topische pharmazeutische formulierungen mit verzögerter freisetzung
|
US7621299B2
(en)
|
2003-10-03 |
2009-11-24 |
Cabot Corporation |
Method and apparatus for filling a vessel with particulate matter
|
EP1677738A2
(de)
*
|
2003-10-31 |
2006-07-12 |
Point Biomedical Corporation |
Rekonstituierbare mikrokugel-zusammensetzungen als ultraschall-kontrastmittel
|
WO2005067898A2
(en)
|
2004-01-07 |
2005-07-28 |
Nektar Therapeutics |
Improved sustained release compositions for pulmonary administration of insulin
|
EP1750668B1
(de)
*
|
2004-04-13 |
2010-02-17 |
Nova Bio-Pharma Technologies Limited |
Flüssigkeiten mit suspendierten glasteilchen
|
ITMI20040795A1
(it)
*
|
2004-04-23 |
2004-07-23 |
Eratech S R L |
Composizione farmaceutica solida secca suo processo di preparazione e sospensione acquosa stabile ottenuta dalla stessa
|
US8012457B2
(en)
|
2004-06-04 |
2011-09-06 |
Acusphere, Inc. |
Ultrasound contrast agent dosage formulation
|
US8513204B2
(en)
|
2004-06-21 |
2013-08-20 |
Novartis Ag |
Compositions comprising amphotericin B, mehods and systems
|
BRPI0512326A
(pt)
|
2004-06-21 |
2008-02-26 |
Nektar Therapeutics |
composições compreendendo anfotericina b, métodos e sistemas
|
WO2006016530A1
(ja)
|
2004-08-10 |
2006-02-16 |
Translational Research, Ltd. |
速効性でかつ高い吸収性を可能とする経鼻投与用組成物
|
ES2355735T5
(es)
|
2004-08-13 |
2014-06-27 |
Boehringer Ingelheim International Gmbh |
Formulación en comprimidos de liberación extendida que contiene pramipexol o una de sus sales farmac�uticamente aceptables, método para su fabricación y su uso
|
EP2431026A1
(de)
|
2004-08-13 |
2012-03-21 |
Boehringer Ingelheim International GmbH |
Pelletformulierung mit verlängerter Wirkstofffreigabe, die Pramipexol oder ein pharmazeutisch unbedenkliches Salz davon enthält, Verfahren zu deren Herstellung und deren Verwendung
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
EA200702049A1
(ru)
|
2005-03-23 |
2008-02-28 |
Элан Фарма Интернэшнл Лтд. |
Композиции наночастиц кортикостероидов с антигистаминами
|
PE20061324A1
(es)
|
2005-04-29 |
2007-01-15 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, metodos y usos
|
WO2006124446A2
(en)
*
|
2005-05-12 |
2006-11-23 |
Nektar Therapeutics |
Sustained release microparticles for pulmonary delivery
|
AU2006287934B2
(en)
|
2005-05-18 |
2012-12-13 |
Nektar Therapeutics |
Valves, devices, and methods for endobronchial therapy
|
PA8675801A1
(es)
|
2005-05-19 |
2006-12-07 |
Centocor Inc |
Anticuerpos anti-mcp-1, composiciones, metodos y usos
|
HUE042561T2
(hu)
|
2005-06-30 |
2019-07-29 |
Janssen Biotech Inc |
Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások
|
ITMI20051999A1
(it)
|
2005-10-21 |
2007-04-22 |
Eratech S R L |
Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
|
JP5113328B2
(ja)
*
|
2005-11-07 |
2013-01-09 |
田辺三菱製薬株式会社 |
エマルション並びにそれを用いた目的物質粒子の製造方法及び医薬品
|
WO2007075534A2
(en)
|
2005-12-16 |
2007-07-05 |
Nektar Therapeutics Al, Corporation |
Polymer conjugates of glp-1
|
DK3219328T3
(da)
|
2005-12-29 |
2020-07-13 |
Janssen Biotech Inc |
Humane anti-il-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser
|
WO2007086039A1
(en)
*
|
2006-01-27 |
2007-08-02 |
The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin |
A method of producing porous microparticles
|
JP5143131B2
(ja)
|
2006-05-30 |
2013-02-13 |
インターシア セラピューティクス,インコーポレイティド |
浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
|
PL2359808T3
(pl)
|
2006-08-09 |
2013-10-31 |
Intarcia Therapeutics Inc |
Osmotyczne systemy dostawcze i zespoły tłokowe
|
WO2008078730A1
(ja)
|
2006-12-26 |
2008-07-03 |
Translational Research, Ltd. |
経鼻投与用製剤
|
WO2008112661A2
(en)
|
2007-03-09 |
2008-09-18 |
Alexza Pharmaceuticals, Inc. |
Heating unit for use in a drug delivery device
|
MX2009011123A
(es)
|
2007-04-23 |
2009-11-02 |
Intarcia Therapeutics Inc |
Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
|
WO2009023803A2
(en)
*
|
2007-08-15 |
2009-02-19 |
Abbott Respiratory Llc |
Modulated release formulation for the delivery of one or more medicaments
|
EP2240155B1
(de)
|
2008-02-13 |
2012-06-06 |
Intarcia Therapeutics, Inc |
Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
|
WO2009120619A2
(en)
*
|
2008-03-24 |
2009-10-01 |
Novartis Ag |
Nuclease compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions
|
PL220269B1
(pl)
|
2008-04-21 |
2015-09-30 |
Przedsiębiorstwo Produkcji Farmaceutycznej Hasco Lek Spółka Akcyjna |
Kompozytowy nośnik leków proszkowych, sposób wytwarzania nośnika leków oraz urządzenie do wytwarzania cząstek nośnika kompozytowego
|
EP2285345A1
(de)
|
2008-05-15 |
2011-02-23 |
Novartis AG |
Pulmonale freisetzung eines fluorchinolons
|
CA2737040C
(en)
|
2008-09-19 |
2017-05-02 |
Nektar Therapeutics |
Polymer conjugates of therapeutic peptides
|
AU2009308935B2
(en)
|
2008-10-31 |
2015-02-26 |
Janssen Biotech, Inc. |
Fibronectin type III domain based scaffold compositions, methods and uses
|
RU2565438C2
(ru)
*
|
2008-11-04 |
2015-10-20 |
Сипла Лимитед |
Фармацевтическая аэрозольная композиция
|
US9925282B2
(en)
|
2009-01-29 |
2018-03-27 |
The General Hospital Corporation |
Cromolyn derivatives and related methods of imaging and treatment
|
EP2396011B1
(de)
|
2009-02-12 |
2016-04-13 |
Janssen Biotech, Inc. |
Auf fibronectin-typ-iii-domain basierende gerüstzusammensetzungen, verfahren und anwendung
|
EP2221048A1
(de)
|
2009-02-18 |
2010-08-25 |
Siegfried Generics International AG |
Pharmazeutische Zusammensetzungen zur Inhalation
|
EP2413902B1
(de)
|
2009-03-18 |
2019-07-17 |
Incarda Therapeutics, Inc. |
Einheitsdosen, aerosole, kits und verfahren zur behandlung von herzleiden mittels inhalativer verabreichung
|
EP2410981B2
(de)
|
2009-03-26 |
2020-02-26 |
Pulmatrix Operating Company, Inc. |
Trockenpulverformulierungen und verfahren zur behandlung von lungenerkrankungen
|
GB0908129D0
(en)
*
|
2009-05-12 |
2009-06-24 |
Innovata Ltd |
Composition
|
KR20100123240A
(ko)
*
|
2009-05-15 |
2010-11-24 |
포항공과대학교 산학협력단 |
호흡기 염증성 질환의 치료 또는 예방을 위한 호흡기내 투여용 약학 제제 및 상기 질환의 치료 또는 예방 방법
|
WO2010131486A1
(en)
|
2009-05-15 |
2010-11-18 |
Shin Nippon Biomedical Laboratories, Ltd. |
Intranasal pharmaceutical compositions with improved pharmacokinetics
|
EP2435023B1
(de)
|
2009-05-29 |
2016-07-06 |
Pearl Therapeutics, Inc. |
Zusammensetzung für die pulmonale freisetzung von muskarinischen antagonisten mit langzeitwirkung und adrenergischen beta-2-rezeptoragonisten mit langzeitwirkung sowie zugehörige verfahren und systeme
|
US8815258B2
(en)
|
2009-05-29 |
2014-08-26 |
Pearl Therapeutics, Inc. |
Compositions, methods and systems for respiratory delivery of two or more active agents
|
GB2472327B
(en)
|
2009-07-31 |
2013-03-13 |
Shin Nippon Biomedical Lab Ltd |
Intranasal granisetron and nasal applicator
|
NZ598686A
(en)
|
2009-09-28 |
2014-05-30 |
Intarcia Therapeutics Inc |
Rapid establishment and/or termination of substantial steady-state drug delivery
|
CN102811715A
(zh)
*
|
2009-12-08 |
2012-12-05 |
悉尼大学 |
可吸入制剂
|
US8758824B2
(en)
|
2010-08-30 |
2014-06-24 |
Pulmatrix, Inc. |
Respirably dry powder comprising calcium lactate, sodium chloride and leucine
|
US9061352B2
(en)
|
2010-08-30 |
2015-06-23 |
Pulmatrix, Inc. |
Dry powder formulations and methods for treating pulmonary diseases
|
RU2017144619A
(ru)
|
2010-09-29 |
2019-02-20 |
Пулмэтрикс, Инк. |
Катионы одновалентных металлов сухих порошков для ингаляций
|
PT3470057T
(pt)
|
2010-09-29 |
2021-12-03 |
Pulmatrix Operating Co Inc |
Pós secos catiónicos compreendendo sais de magnésio
|
CN103228266B
(zh)
|
2010-10-29 |
2017-11-14 |
健康科学西部大学 |
三元混合物制剂
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
WO2012116362A2
(en)
*
|
2011-02-25 |
2012-08-30 |
The Johns Hopkins University |
Chalcone derivatives as nrf2 activators
|
GB201108039D0
(en)
*
|
2011-05-13 |
2011-06-29 |
Mexichem Amanco Holding Sa |
Compositions
|
CN103687483A
(zh)
*
|
2011-05-17 |
2014-03-26 |
珍珠治疗公司 |
用于呼吸递送两种或多种活性剂的组合物、方法和系统
|
GB201117619D0
(en)
|
2011-10-12 |
2011-11-23 |
Mexichem Amanco Holding Sa |
Compositions
|
GB201117621D0
(en)
*
|
2011-10-12 |
2011-11-23 |
Mexichem Amanco Holding Sa |
Compositions
|
EP2601941A1
(de)
|
2011-12-06 |
2013-06-12 |
Ludwig-Maximilians-Universität München |
Verbindungen auf beta-O/S/N-Fettsäurebasis als Antibakterium- und Antiprotozoenmittel
|
BR112014025518B1
(pt)
|
2012-04-13 |
2022-05-24 |
Glaxosmithkline Intellectual Property Development Limited |
Partículas agregadas de umeclidinium, vilanterol e fluticasona, composição em pó, inalador, processo para a preparação de partículas agregadas, e, uso de estearato de magnésio em partículas agregadas
|
EP2911664B1
(de)
|
2012-10-25 |
2019-05-08 |
The General Hospital Corporation |
Kombinationstherapien zur behandlung von morbus alzheimer und verwandten erkrankungen
|
AU2014228414B2
(en)
|
2013-03-15 |
2018-09-13 |
Pearl Therapeutics, Inc. |
Methods and systems for conditioning of particulate crystalline materials
|
GB201306984D0
(en)
|
2013-04-17 |
2013-05-29 |
Mexichem Amanco Holding Sa |
Composition
|
WO2014178891A1
(en)
|
2013-04-30 |
2014-11-06 |
Otitopic Inc. |
Dry powder formulations and methods of use
|
KR101543507B1
(ko)
*
|
2013-05-15 |
2015-08-11 |
씨제이헬스케어 주식회사 |
연속 공정의 미립구의 제조 방법 및 이로부터 제조된 미립구
|
US10525005B2
(en)
|
2013-05-23 |
2020-01-07 |
The General Hospital Corporation |
Cromolyn compositions and methods thereof
|
MX2015016102A
(es)
*
|
2013-05-23 |
2016-08-08 |
Aztherapies Inc |
Metodos para la liberacion de cromolina.
|
WO2014207213A1
(en)
|
2013-06-28 |
2014-12-31 |
Medizinische Universität Innsbruck |
Novel inhibitors of protein kinase c epsilon signaling
|
CA2928028A1
(en)
|
2013-10-22 |
2015-04-30 |
The General Hospital Corporation |
Cromolyn derivatives and related methods of imaging and treatment
|
HUE049323T2
(hu)
|
2014-02-10 |
2020-09-28 |
Respivant Sciences Gmbh |
Hízósejt-stabilizálók tüdõbetegség kezelésére
|
PT3104853T
(pt)
|
2014-02-10 |
2020-01-14 |
Respivant Sciences Gmbh |
Tratamento com estabilizadores de mastócitos para distúrbios sistémicos
|
WO2015127315A1
(en)
|
2014-02-20 |
2015-08-27 |
Otitopic Inc. |
Dry powder formulations for inhalation
|
EP2947460A1
(de)
|
2014-05-22 |
2015-11-25 |
Medizinische Universität Wien |
Personalisierte Therapie von Entzündungen um Zusammenhang mit Krebs mithilfe von Verfahren zur Bestimmung der Empfänglichkeit auf die Behandlung mit EGFR-Hemmern/-Antagonisten
|
CA2991760A1
(en)
|
2014-07-31 |
2016-02-04 |
Otitopic Inc. |
Dry powder formulations for inhalation
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
CN107106641B
(zh)
|
2014-10-31 |
2021-12-21 |
葛兰素史密斯克莱知识产权发展有限公司 |
粉末制剂
|
JP6395216B2
(ja)
*
|
2014-11-13 |
2018-09-26 |
国立大学法人大阪大学 |
液体に含まれる超微細バブルの測定方法及びその測定装置
|
WO2016118625A1
(en)
|
2015-01-20 |
2016-07-28 |
Incarda Therapeutics, Inc. |
Unit aerosol doses for anticoagulation
|
WO2016135137A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135140A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135138A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135139A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
US10864190B2
(en)
|
2015-04-22 |
2020-12-15 |
CeMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH |
Combination of an antiandrogen with a vitamin K antagonist or with a gamma-glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
|
AU2016270984B2
(en)
|
2015-06-03 |
2021-02-25 |
Intarcia Therapeutics, Inc. |
Implant placement and removal systems
|
EP3331522A1
(de)
|
2015-08-07 |
2018-06-13 |
Patara Pharma LLC |
Verfahren zur behandlung von mastzellbedingten erkrankungen mit mastzellstabilisatoren
|
US10265296B2
(en)
|
2015-08-07 |
2019-04-23 |
Respivant Sciences Gmbh |
Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
|
BR122020022602B1
(pt)
|
2015-12-04 |
2024-03-05 |
Mexichem Fluor S.A. De C.V. |
Composição farmacêutica
|
WO2017097986A1
(en)
|
2015-12-09 |
2017-06-15 |
Medizinische Universität Wien |
Monomaleimide-functionalized platinum compounds for cancer therapy
|
JP2019508383A
(ja)
|
2016-01-15 |
2019-03-28 |
ウニベルジテート ハンブルグUniversitaet Hamburg |
O−ラムノシル残基を有するフラボノイド型化合物
|
IL260335B2
(en)
|
2016-02-01 |
2023-10-01 |
Incarda Therapeutics Inc |
Combining electronic monitoring with inhaled pharmacological therapy for the management of cardiac arrhythmia including atrial fibrillation
|
US10702518B2
(en)
|
2016-02-15 |
2020-07-07 |
CeMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH |
TAF1 inhibitors for the therapy of cancer
|
AU2017241776A1
(en)
|
2016-03-29 |
2018-10-11 |
Janssen Biotech, Inc. |
Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody
|
EP3280414B1
(de)
|
2016-04-15 |
2023-08-23 |
Oxford University Innovation Limited |
Adenosin-rezeptormodulatoren zur behandlung von biorhythmusschwankungen
|
CN109310743A
(zh)
|
2016-05-16 |
2019-02-05 |
因塔西亚制药公司 |
胰高血糖素受体选择性多肽及其使用方法
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
WO2018014039A1
(en)
|
2016-07-15 |
2018-01-18 |
Poseida Therapeutics, Inc. |
Chimeric antigen receptors (cars) specific for muc1 and methods for their use
|
BR112019000683A2
(pt)
|
2016-07-15 |
2019-04-24 |
Poseida Therapeutics Inc |
receptores de antígeno quiméricos e métodos para uso
|
WO2018045217A1
(en)
|
2016-08-31 |
2018-03-08 |
The General Hospital Corporation |
Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
|
AU2017321495A1
(en)
|
2016-08-31 |
2019-03-21 |
Respivant Sciences Gmbh |
Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
|
IL265349B2
(en)
|
2016-09-19 |
2023-03-01 |
Mexichem Fluor Sa De Cv |
Pharmaceutical composition
|
MX2019003099A
(es)
|
2016-09-19 |
2019-06-10 |
Mexichem Fluor Sa De Cv |
Composicion farmaceutica.
|
BR112019005133A2
(pt)
|
2016-09-19 |
2019-06-04 |
Mexichem Fluor Sa De Cv |
composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente sofrendo ou susceptível de sofrer de um distúrbio respiratório, para melhorar a estabilidade de uma composição farmacêutica, para melhoria do desempenho de dispersão em aerossol de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica.
|
ES2891579T3
(es)
|
2016-09-19 |
2022-01-28 |
Mexichem Fluor Sa De Cv |
Composición farmacéutica
|
KR20190059305A
(ko)
|
2016-09-30 |
2019-05-30 |
얀센 바이오테크 인코포레이티드 |
항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법
|
WO2018067341A1
(en)
|
2016-10-07 |
2018-04-12 |
Patara Pharma, LLC |
Cromolyn compositions for treatment of pulmonary fibrosis
|
MX2019005443A
(es)
|
2016-11-14 |
2019-11-21 |
Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh |
Combinacion de un inhibidor de brd4 y un antifolato para la terapia del cancer.
|
WO2018093841A1
(en)
|
2016-11-16 |
2018-05-24 |
Janssen Biotech, Inc. |
Method of treating psoriasis with anti-il-23 specific antibody
|
EP3565580B1
(de)
|
2017-01-03 |
2024-03-06 |
i2o Therapeutics, Inc. |
Kontinuierlicher verabreichung von exenatid und co-verabreichung von acetaminophen, ethinylestradiol oder levonorgestrel
|
EP3621616A4
(de)
|
2017-05-10 |
2021-01-13 |
InCarda Therapeutics, Inc. |
Einheitsdosen, aerosole, kits und verfahren zur behandlung von herzleiden mittels pulmonaler verabreichung
|
AU2018273887B2
(en)
|
2017-05-22 |
2022-09-08 |
Insmed Incorporated |
Lipo-glycopeptide cleavable derivatives and uses thereof
|
MX2020000577A
(es)
|
2017-07-20 |
2020-09-10 |
Aztherapies Inc |
Formulaciones en polvo de cromolina sodica e ibuprofeno.
|
EP3679145A2
(de)
|
2017-09-08 |
2020-07-15 |
Poseida Therapeutics, Inc. |
Zusammensetzungen und verfahren für durch chimären ligandenrezeptor (clr) vermittelte bedingte genexpression
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
US11744967B2
(en)
|
2017-09-26 |
2023-09-05 |
Shin Nippon Biomedical Laboratories, Ltd. |
Intranasal delivery devices
|
WO2019110139A1
(en)
|
2017-12-05 |
2019-06-13 |
Eth Zurich |
New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
|
US20210139557A1
(en)
|
2017-12-20 |
2021-05-13 |
Poseida Therapeutics, Inc. |
Vcar compositions and methods for use
|
EP3762015A4
(de)
|
2018-03-05 |
2022-04-27 |
Janssen Biotech, Inc. |
Verfahren zur behandlung von morbus crohn mit anti-il23-spezifischem antikörper
|
WO2019173636A1
(en)
|
2018-03-07 |
2019-09-12 |
Poseida Therapeutics, Inc. |
Cartyrin compositions and methods for use
|
US10744087B2
(en)
|
2018-03-22 |
2020-08-18 |
Incarda Therapeutics, Inc. |
Method to slow ventricular rate
|
US20210163406A1
(en)
|
2018-04-06 |
2021-06-03 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs
|
BR112020020464A2
(pt)
|
2018-04-06 |
2021-01-12 |
Zilentin AG |
Derivados de bumetanida para a terapia da hiperidrose
|
JP2021523138A
(ja)
|
2018-05-11 |
2021-09-02 |
ヤンセン バイオテツク,インコーポレーテツド |
Il−23抗体を使用してうつを治療する方法
|
US10414721B1
(en)
|
2018-06-04 |
2019-09-17 |
University Of Bern |
Inhibitor of endocannabinoid cellular reuptake
|
KR20210071943A
(ko)
|
2018-07-02 |
2021-06-16 |
더 제너럴 하스피탈 코포레이션 |
크로몰린 소듐 및 α-락토스의 분말화된 제형
|
WO2020016838A2
(en)
|
2018-07-18 |
2020-01-23 |
Janssen Biotech, Inc. |
Sustained response predictors after treatment with anti-il23 specific antibody
|
KR20230148273A
(ko)
|
2018-09-24 |
2023-10-24 |
얀센 바이오테크 인코포레이티드 |
항-il12/il23 항체로 궤양성 결장염을 치료하는 안전하고 효과적인 방법
|
CN113395979A
(zh)
|
2018-11-20 |
2021-09-14 |
詹森生物科技公司 |
用抗il-23特异性抗体治疗银屑病的安全且有效的方法
|
EP3898614A1
(de)
|
2018-12-17 |
2021-10-27 |
Tolremo Therapeutics AG |
Heterocyclische derivate, pharmazeutische zusammensetzungen und deren verwendung in der behandlung, linderung oder vorbeugung von krebserkrankungen
|
US20200197517A1
(en)
|
2018-12-18 |
2020-06-25 |
Janssen Biotech, Inc. |
Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
|
CA3125622C
(en)
|
2019-01-03 |
2023-09-26 |
Aqua Yield Operations LLC |
Pamam dendrimers for fertilizer delivery
|
CN113825765A
(zh)
|
2019-03-14 |
2021-12-21 |
詹森生物科技公司 |
用于制备抗il12/il23抗体组合物的制造方法
|
US20200331996A1
(en)
|
2019-03-18 |
2020-10-22 |
Janssen Biotech, Inc. |
Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody
|
US11932585B2
(en)
|
2019-04-12 |
2024-03-19 |
Aqua Yield Operations LLC |
Blended nanoparticle fertilizer delivery
|
CN110051868A
(zh)
*
|
2019-04-15 |
2019-07-26 |
宝盈联华(厦门)生物科技有限公司 |
一种带有硅碳岩、礌石粉的橱柜灭菌器
|
JP7404671B2
(ja)
*
|
2019-06-25 |
2023-12-26 |
株式会社リコー |
多孔質微粒子及びその製造方法、並びに医薬組成物
|
US11020384B2
(en)
|
2019-08-01 |
2021-06-01 |
Incarda Therapeutics, Inc. |
Antiarrhythmic formulation
|
WO2021064141A1
(en)
|
2019-10-02 |
2021-04-08 |
Tolremo Therapeutics Ag |
Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
|
CN114728934A
(zh)
|
2019-10-02 |
2022-07-08 |
托雷莫治疗股份公司 |
杂环衍生物、药物组合物和它们治疗或改善癌症的用途
|
WO2021074418A1
(en)
|
2019-10-16 |
2021-04-22 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
EP4045142A1
(de)
|
2019-10-16 |
2022-08-24 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Oxazol- und thioazin-ring-ubiquitin-ligase-verbindungen und verwendungen davon
|
CN115996747A
(zh)
|
2020-04-14 |
2023-04-21 |
波赛达治疗公司 |
用于治疗癌症的组合物和方法
|
EP4138884A1
(de)
|
2020-04-20 |
2023-03-01 |
Sorrento Therapeutics, Inc. |
Pulmonale verabreichung von ace2-polypeptiden
|
WO2021214588A1
(en)
|
2020-04-21 |
2021-10-28 |
Janssen Biotech, Inc. |
Anti-tnf alpha agent for treating coronavirus infections
|
WO2021214587A1
(en)
|
2020-04-21 |
2021-10-28 |
Janssen Biotech, Inc. |
Anti-tnf alpha agent for treating viral infections
|
US20230226057A1
(en)
|
2020-06-25 |
2023-07-20 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
|
EP3939578A1
(de)
|
2020-07-13 |
2022-01-19 |
Novaremed Ltd. |
Verbindungen zur behandlung oder vorbeugung einer infektion, die aus einer coronavirus- und/oder einer coronavirusinduzierten erkrankung resultiert
|
CN111700883B
(zh)
*
|
2020-07-23 |
2021-04-06 |
深圳大佛药业股份有限公司 |
一种硫酸沙丁胺醇缓释型吸入制剂及其生产工艺
|
US20230270669A1
(en)
|
2020-09-04 |
2023-08-31 |
Mexichem Fluor S.A. De C.V. |
Pharmaceutical composition
|
EP3964497A1
(de)
|
2020-09-04 |
2022-03-09 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Substituierte vicinale diaminverbindungen und deren verwendung zur behandlung, linderung oder vorbeugung von schmerzen
|
WO2022079290A2
(en)
|
2020-10-16 |
2022-04-21 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Cullin ring ubiquitin ligase compounds and uses thereof
|
CN112495316B
(zh)
*
|
2020-10-20 |
2021-11-19 |
大连理工大学 |
一种基于亚稳态乳液制备微纳米凝胶微球的方法
|
TW202237102A
(zh)
*
|
2020-12-11 |
2022-10-01 |
大陸商江蘇恒瑞醫藥股份有限公司 |
用於肺部遞送的藥物組合物
|
IL305802A
(en)
|
2021-03-12 |
2023-11-01 |
Janssen Biotech Inc |
A safe and effective method for the treatment of rheumatoid arthritis with a specific anti-IL23 antibody
|
WO2022189662A1
(en)
|
2021-03-12 |
2022-09-15 |
Alvarius Pharmaceuticals Ltd. |
Compositions and methods for treating addictions comprising 5-meo-dmt
|
WO2022190034A1
(en)
|
2021-03-12 |
2022-09-15 |
Janssen Biotech, Inc. |
Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
|
EP4320109A1
(de)
|
2021-04-07 |
2024-02-14 |
Tolremo Therapeutics AG |
Heterocyclische derivate, pharmazeutische zusammensetzungen und deren verwendung bei der behandlung oder linderung von krebs
|
IL309987A
(en)
|
2021-07-09 |
2024-03-01 |
Janssen Biotech Inc |
Production methods for the production of anti-IL12/IL23 antibody compositions
|
WO2023073615A1
(en)
|
2021-10-29 |
2023-05-04 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
WO2023084488A1
(en)
|
2021-11-15 |
2023-05-19 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
US20230159633A1
(en)
|
2021-11-23 |
2023-05-25 |
Janssen Biotech, Inc. |
Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
|
WO2023187707A1
(en)
|
2022-03-30 |
2023-10-05 |
Janssen Biotech, Inc. |
Method of treating mild to moderate psoriasis with il-23 specific antibody
|
WO2023203172A1
(en)
|
2022-04-20 |
2023-10-26 |
Proxygen Gmbh |
Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
|
US20230374122A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
|